DAWN241220C12500
- 0.25
- +0.05+25.00%
Day One Biopharmaceuticals Newsroom
Day One Biopharm Is Maintained at Buy by Jones Trading
Day One Biopharmaceutical Analyst Ratings
Day One Biopharmaceuticals (DAWN) Posts Stellar Q3 but With Extreme Concentration Risk
JonesTrading Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Cuts Target Price to $34
CBTN Partners With Day One to Drive New Therapies for Pediatric Brain Tumors
Piper Sandler Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Maintains Target Price $40
Bonum Therapeutics Appoints Samuel C. Blackman, MD, PhD, to Its Board of Directors
Why Is Day One Biopharmaceuticals Inc. (DAWN) Among the Best Up and Coming Stocks to Buy According to Analysts?
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
Express News | Day One Announces Retirement of DR. Samuel Blackman, Co-Founder and Head of Research & Development
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas
Day One Biopharmaceuticals Insider Sold Shares Worth $456,223, According to a Recent SEC Filing
Express News | Day One Biopharmaceuticals Inc : JP Morgan Raises Target Price to $39 From $36
J.P. Morgan Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating
Day One Biopharmaceuticals: Strong Ojemda Launch Exceeds Expectations, Analyst Reiterates Overweight Rating
Bullish: Analysts Just Made A Huge Upgrade To Their Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Forecasts
Day One Biopharmaceuticals, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Easily Afford To Drive Business Growth
A Quick Look at Today's Ratings for Day One Biopharmaceuticals(DAWN.US), With a Forecast Between $28 to $40
HC Wainwright & Co. Reiterates Buy on Day One Biopharmaceutical, Maintains $40 Price Target